|
|
Volumn 279, Issue 9, 1998, Pages 645-
|
|
Tobramycin inhalation product approved for use in cystic fibrosis therapy
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
TOBRAMYCIN;
GENERIC DRUG;
ANTIINFECTIVE AGENT;
LATEX;
CYSTIC FIBROSIS;
DRUG EFFICACY;
FORCED EXPIRATORY VOLUME;
INHALATIONAL DRUG ADMINISTRATION;
LUNG INFECTION;
NOTE;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
BIOEQUIVALENCE;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG QUALITY;
FOOD AND DRUG ADMINISTRATION;
PRESCRIPTION;
ADVERTIZING;
ARTICLE;
DRUG APPROVAL;
HUMAN;
HYPERSENSITIVITY;
STANDARD;
TELECOMMUNICATION;
UNITED STATES;
ADMINISTRATION, INHALATION;
ADVERTISING;
ANTI-BACTERIAL AGENTS;
CYSTIC FIBROSIS;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUGS, GENERIC;
HUMANS;
HYPERSENSITIVITY;
LATEX;
TELECOMMUNICATIONS;
TOBRAMYCIN;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0032481498
PISSN: 00987484
EISSN: None
Source Type: Journal
DOI: 10.1001/jama.279.9.645-JFD80000-3-1 Document Type: Note |
|
Times cited : (16)
|
|
References (0)
|
